Biomarkers of Inflammation, Thrombogenesis, and Collagen Turnover in Patients With Atrial Fibrillation

Overview

Journal Clin Appl Thromb Hemost

Publisher Sage Publications

Specialty Cardiology & Vascular Diseases

Date 2018 Mar 22

PMID 29558818

Citations 16

Authors

Sallu Jabati

Jawed Fareed

Jeffrey Liles

Abigail Otto

Debra Hoppensteadt

Jack Bontekoe

Trung Phan

Amanda Walborn

Mushabbar Syed

Affiliations

Soon will be listed here.

Abstract

The purpose of this study was to determine whether there are any differences in the levels of inflammatory, thrombotic, and collagen turnover biomarkers between individuals with atrial fibrillation (AF) and healthy volunteers. Circulating plasma levels of plasminogen activator inhibitor 1 (PAI-1), CD40-ligand (CD40-L), nucleosomes (which are indicators of cell death), C-reactive protein (CRP), procollagen III N-terminal propeptide (PIIINP), procollagen III C-terminal propeptide (PIIICP), procollagen I N-terminal propeptide, tissue plasminogen activator, and von Willebrand factor were analyzed as potential biomarkers of AF. Baseline plasma was collected from patients with AF prior to ablation surgery at Loyola University Medical Center. Individuals with AF had statistically significantly increased levels of PAI-1, CD40-L, and nucleosomes, when compared to the normal population ( P < .0001). Additionally, there was a statistically significant increase in the CRP ( P = .01), PIIINP ( P = .04), and PIIICP ( P = .0008) when compared to normal individuals. From this study, it is concluded that the prothrombotic, inflammatory, and collagen turnover biomarkers PAI-1, CD40-L, nucleosomes, CRP, PIIICP, and PIIINP are elevated in AF.

Citing Articles

Characterization of Biomarkers of Thrombo-Inflammation in Patients with First-Diagnosed Atrial Fibrillation.

Friebel J, Wegner M, Blobaum L, Schencke P, Jakobs K, Puccini M Int J Mol Sci. 2024; 25(7).

PMID: 38612918 PMC: 11012942. DOI: 10.3390/ijms25074109.

Effect of an Intensive Lifestyle Intervention on Circulating Biomarkers of Atrial Fibrillation-Related Pathways among Adults with Metabolic Syndrome: Results from a Randomized Trial.

Li L, Alonso A, Romaguera D, Alonso-Gomez A, Razquin C, Tojal-Sierra L J Clin Med. 2024; 13(7).

PMID: 38610897 PMC: 11012583. DOI: 10.3390/jcm13072132.

Association between Biomarkers of Inflammation and 10-Year Changes in Aortic Stiffness: The Multi-Ethnic Study of Atherosclerosis.

Swamynathan R, Varadarajan V, Nguyen H, Wu C, Liu K, Bluemke D J Clin Med. 2023; 12(15).

PMID: 37568463 PMC: 10419470. DOI: 10.3390/jcm12155062.

The Possible Influence of Vitamin D Levels on the Development of Atrial Fibrillation-An Update.

Graczyk S, Grzeczka A, Paslawska U, Kordowitzki P Nutrients. 2023; 15(12).

PMID: 37375629 PMC: 10302036. DOI: 10.3390/nu15122725.

The Role of Major Inflammatory Biomarkers in the Pathogenesis of Atrial Fibrillation.

Rafaqat S, Afzal S, Khurshid H, Safdar S, Rafaqat S, Rafaqat S J Innov Card Rhythm Manag. 2023; 13(12):5265-5277.

PMID: 37293559 PMC: 10246921. DOI: 10.19102/icrm.2022.13125.

References

Querejeta R, Varo N, Lopez B, Larman M, Artinano E, Etayo J . Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation. 2000; 101(14):1729-35. DOI: 10.1161/01.cir.101.14.1729. View

Mondillo S, Sabatini L, Agricola E, Ammaturo T, Guerrini F, Barbati R . Correlation between left atrial size, prothrombotic state and markers of endothelial dysfunction in patients with lone chronic nonrheumatic atrial fibrillation. Int J Cardiol. 2000; 75(2-3):227-32. DOI: 10.1016/s0167-5273(00)00336-3. View

Aviles R, Martin D, Apperson-Hansen C, Houghtaling P, Rautaharju P, Kronmal R . Inflammation as a risk factor for atrial fibrillation. Circulation. 2003; 108(24):3006-10. DOI: 10.1161/01.CIR.0000103131.70301.4F. View

Thambidorai S, Parakh K, Martin D, Shah T, Wazni O, Jasper S . Relation of C-reactive protein correlates with risk of thromboembolism in patients with atrial fibrillation. Am J Cardiol. 2004; 94(6):805-7. DOI: 10.1016/j.amjcard.2004.06.011. View

Conway D, Buggins P, Hughes E, Lip G . Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am Heart J. 2004; 148(3):462-6. DOI: 10.1016/j.ahj.2004.01.026. View

BASHEY R, Martinez-Hernandez A, Jimenez S . Isolation, characterization, and localization of cardiac collagen type VI. Associations with other extracellular matrix components. Circ Res. 1992; 70(5):1006-17. DOI: 10.1161/01.res.70.5.1006. View

Polyakova V, Miyagawa S, Szalay Z, Risteli J, Kostin S . Atrial extracellular matrix remodelling in patients with atrial fibrillation. J Cell Mol Med. 2008; 12(1):189-208. PMC: 3823481. DOI: 10.1111/j.1582-4934.2008.00219.x. View

Kallergis E, Manios E, Kanoupakis E, Mavrakis H, Arfanakis D, Maliaraki N . Extracellular matrix alterations in patients with paroxysmal and persistent atrial fibrillation: biochemical assessment of collagen type-I turnover. J Am Coll Cardiol. 2008; 52(3):211-5. DOI: 10.1016/j.jacc.2008.03.045. View

McGann C, Kholmovski E, Oakes R, Blauer J, Daccarett M, Segerson N . New magnetic resonance imaging-based method for defining the extent of left atrial wall injury after the ablation of atrial fibrillation. J Am Coll Cardiol. 2008; 52(15):1263-71. DOI: 10.1016/j.jacc.2008.05.062. View

10.

Rizvi M, Pathak D, Freedman J, Chakrabarti S . CD40-CD40 ligand interactions in oxidative stress, inflammation and vascular disease. Trends Mol Med. 2008; 14(12):530-8. DOI: 10.1016/j.molmed.2008.09.006. View

11.

Holdenrieder S, Stieber P . Clinical use of circulating nucleosomes. Crit Rev Clin Lab Sci. 2008; 46(1):1-24. DOI: 10.1080/10408360802485875. View

12.

Oakes R, Badger T, Kholmovski E, Akoum N, Burgon N, Fish E . Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. Circulation. 2009; 119(13):1758-67. PMC: 2725019. DOI: 10.1161/CIRCULATIONAHA.108.811877. View

13.

Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos A, Stefanadis C . The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol. 2009; 54(8):669-77. DOI: 10.1016/j.jacc.2009.03.076. View

14.

Naccarelli G, Varker H, Lin J, Schulman K . Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009; 104(11):1534-9. DOI: 10.1016/j.amjcard.2009.07.022. View

15.

Gavins F, Li G, Russell J, Perretti M, Granger D . Microvascular thrombosis and CD40/CD40L signaling. J Thromb Haemost. 2010; 9(3):574-81. PMC: 3050075. DOI: 10.1111/j.1538-7836.2010.04176.x. View

16.

Van De Craen B, Declerck P, Gils A . The Biochemistry, Physiology and Pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo. Thromb Res. 2012; 130(4):576-85. DOI: 10.1016/j.thromres.2012.06.023. View

17.

Shenkman B, Livnat T, Budnik I, Tamarin I, Einav Y, Martinowitz U . Plasma tissue-type plasminogen activator increases fibrinolytic activity of exogenous urokinase-type plasminogen activator. Blood Coagul Fibrinolysis. 2012; 23(8):729-33. DOI: 10.1097/MBC.0b013e32835897d5. View

18.

Thacker E, McKnight B, Psaty B, Longstreth Jr W, Dublin S, Jensen P . Association of body mass index, diabetes, hypertension, and blood pressure levels with risk of permanent atrial fibrillation. J Gen Intern Med. 2012; 28(2):247-53. PMC: 3614136. DOI: 10.1007/s11606-012-2220-4. View

19.

Guo Y, Lip G, Apostolakis S . Inflammation in atrial fibrillation. J Am Coll Cardiol. 2012; 60(22):2263-70. DOI: 10.1016/j.jacc.2012.04.063. View

20.

Colilla S, Crow A, Petkun W, Singer D, Simon T, Liu X . Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013; 112(8):1142-7. DOI: 10.1016/j.amjcard.2013.05.063. View